COVID Vaccine ‘Miracle’ May Set Unrealistic Expectations For US Supply Chains
The story of the US coronavirus vaccine production ramp-up is putting the drug industry in an extraordinarily favorable public relations position. One downside, however, may be complicating the industry’s message about the limits of ‘Buy American’ efforts on pharmaceutical supply chains overall.
You may also be interested in...
Pharma Gets Warm Spotlight At White House Event Showcasing J&J-Merck Collaboration
Biden Administration seeks to put its stamp on a new phase of the US government’s collaboration with the pharma industry against COVID-19.
US FDA And Congressional Oversight: Will Democrats Be Tougher Than The GOP?
Most US agencies can expect relatively friendly oversight from a Democratic Congress. The US FDA might be one exception, as a recent House hearing on foreign inspections shows.
A New Start: President Biden Visits Pfizer
President Biden’s relationship with the US pharmaceutical industry is starting out with the starkest contrast imaginable with the initial approach of the Trump Administration – at least on the symbolic level.